What is Alto Neuroscience's payments of debt issuance costs?

Alto Neuroscience (ANRO) reported payments of debt issuance costs of $0 in Q1 2026.

How has Alto Neuroscience's payments of debt issuance costs changed year-over-year?

Alto Neuroscience's payments of debt issuance costs decreased by 100.0% year-over-year, from $127K to $0.

Alto Neuroscience ANRO Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

AlkermesALKS

——

Arrowhead ResearchARWR

——

Tempus AI, Inc.TEM

——

RevvityRVTY

——

Other financials

Income statement

See full

Operating income-$27.1M-73.1%

Net income-$26.2M-73.0%

EPS (diluted)-$0.80-42.9%

Balance sheet

See full

Cash & equivalents$264.3M+63.9%

Total debt$20.9M-17.2%

Total equity$243.4M+75.0%

Total assets$276.3M+60.7%

Cash flow

See full

Operating cash flow-$27.1M-63.6%

CapEx$556.0K+2,217%

Free cash flow-$27.6M-66.7%

Valuation

See full

Market cap$887.88M+1,358%

Enterprise value$644.49M-958%

Returns & leverage

See full

Return on equity-38.9%+0.9pp

Debt / equity0.1×-0.1×

Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alto Neuroscience's payments of debt issuance costs?: Alto Neuroscience (ANRO) reported payments of debt issuance costs of $0 in Q1 2026.
How has Alto Neuroscience's payments of debt issuance costs changed year-over-year?: Alto Neuroscience's payments of debt issuance costs decreased by 100.0% year-over-year, from $127K to $0.